End-to-end vector manufacturing optimizes batch success and delivers more doses at lower cost.
The U.S. health regulator has approved Roche Holding AG’s therapy for treating a type of rare cancer called follicular lymphoma.
A separation of Sandoz via a 100 percent spin-off will create the leading European generics company and a global leader in biosimilars, and a more focused Novartis.
The naming of brands is a difficult matter.
The long weekend saw three established drugs developed by Bristol Myers Squibb, Novartis, and Roche score new approvals from the U.S. Food and Drug Administration.